Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease

This study has been completed.
Information provided by (Responsible Party):
University of Erlangen-Nürnberg Medical School Identifier:
First received: March 18, 2009
Last updated: July 6, 2012
Last verified: July 2012
The Renin-Angiotensin-Aldosterone-system is important in the development of cardiovascular organ damage caused by arterial hypertension. This study aims at evaluating the importance of aldosterone with regard to hypertension induced damage to the heart. In order to do this the investigators will perform a comparative cross-sectional study in hypertensives and normotensives. In addition as interventional part the hypertensives will be treated with a mineralocorticoid-receptor blocker (spironolactone).

Condition Intervention Phase
Primary Hypertension
Drug: spironolactone
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease

Resource links provided by NLM:

Further study details as provided by University of Erlangen-Nürnberg Medical School:

Primary Outcome Measures:
  • left ventricular mass [ Time Frame: 8 weeks ]

Enrollment: 50
Study Start Date: March 2008
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: spironolactone
25mg per oral once daily
Placebo Comparator: 2
Drug: placebo


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis hypertension (BP higher than 139/89)

Exclusion Criteria:

  • Antihypertensive pretreatment
  • Contraindications against spironolactone
  • Being unable to understand or comply with study procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00865501

University Erlangen-Nürnberg, Nephrology and Hypertension
Erlangen, Germany, 91054
Sponsors and Collaborators
University of Erlangen-Nürnberg Medical School
Principal Investigator: Roland E Schmieder, MD, FACP Universität Erlangen-Nurnberg
  More Information

Responsible Party: University of Erlangen-Nürnberg Medical School Identifier: NCT00865501     History of Changes
Other Study ID Numbers: KFO-TP5-I
Study First Received: March 18, 2009
Last Updated: July 6, 2012

Keywords provided by University of Erlangen-Nürnberg Medical School:
primary hypertension
left ventricular hypertrophy

Additional relevant MeSH terms:
Heart Diseases
Vascular Diseases
Cardiovascular Diseases
Mineralocorticoid Receptor Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Diuretics, Potassium Sparing
Natriuretic Agents processed this record on May 25, 2017